Page 10 - Flipbook

Keynote-564 results

• Disease-free survival: 77% vs 68% (HR 0.68 95%CI 0.53-0.87)

• Consistent across subgroups

• Alive at 24 months: 96.6% vs 93.5% (HR 0.54, 0.30-0.96)

• Grade 3 A/Es: 32.4% vs. 17.7%

• 21% of patients discontinued regimen due to A/E

• Conclude:

• Pembro improves DFS, may improve OS

• Encouraging, but need OS before widespread

use in my opinion